NCT05687123 2026-03-18
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
57 trialsNCT05691465 2026-03-18
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05724108 2026-03-18
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05773274 2026-03-18
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04665739 2026-03-17
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04750954 2026-03-17
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05142696 2026-03-17
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Novartis
Phase 1/2 Active not recruiting
NCT05109728 2026-03-16
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Novartis
Phase 1 Active not recruiting
NCT03971461 2026-03-11
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
NYU Langone Health
Phase 2 Active not recruiting
NCT03206060 2026-02-17
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06955169 2026-02-17
MOMENTUM-1
RTOG Foundation, Inc.
Phase 2 Recruiting
NCT04711135 2026-02-12
NETTER-P
Advanced Accelerator Applications
Phase 2 Active not recruiting
NCT04954820 2026-02-05
ReLUTH
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Recruiting
NCT03972488 2026-01-21
NETTER-2
Advanced Accelerator Applications
Phase 3 Active not recruiting
NCT06122610 2026-01-15
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
University of Wisconsin, Madison
Phase 1 Recruiting
NCT05987176 2026-01-14
NELMAS
Imperial College London
Phase 2 Terminated
NCT06663072 2026-01-09
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
University of Chicago
Phase 1 Recruiting
NCT04234568 2025-12-22
Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04086485 2025-12-17
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06016855 2025-12-17
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Vanderbilt-Ingram Cancer Center
Phase 4 Recruiting
NCT04082520 2025-12-11
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Mayo Clinic
Phase 2 Recruiting
NCT02743741 2025-12-03
Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
University Health Network, Toronto
Phase NA Active not recruiting
NCT05178693 2025-11-24
LANTana
Imperial College London
Phase 1 Recruiting
NCT03966651 2025-11-18
NEUROBLU 02
Institut Claudius Regaud
Phase 1 Recruiting
NCT05278208 2025-10-20
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nationwide Children's Hospital
Phase 1/2 Recruiting
NCT06326190 2025-09-16
LUMEN-1
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Recruiting
NCT04609592 2025-09-09
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
Stanford University
Phase 1 Recruiting
NCT06398444 2025-09-05
A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
Sinotau Pharmaceutical Group
Phase 2/3 Active not recruiting
NCT03457948 2025-09-03
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
University of California, San Francisco
Phase 2 Active not recruiting
NCT06878664 2025-09-02
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
NCT06395402 2025-07-22
LUMOD-ID
University of Iowa
Phase 2 Recruiting
NCT07012330 2025-06-10
Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients
Erasmus Medical Center
Phase 2 Terminated
NCT05583708 2025-05-23
iPRRT
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT04544098 2025-05-02
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT02230176 2025-04-20
OCCLURANDOM
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT05247905 2025-04-02
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT05249114 2025-03-10
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Providence Health & Services
Phase 1 Active not recruiting
NCT04261855 2025-02-14
GoTHAM
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Recruiting
NCT04903899 2025-02-11
LuDO-N
Karolinska University Hospital
Phase 2 Recruiting
NCT02489604 2025-01-13
LUNET
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Terminated
NCT06607692 2024-10-21
LUPARPED
Fundación de investigación HM
Phase 2 Recruiting
NCT02236910 2024-10-15
Lu-DOTA-TATE
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2 Unknown
NCT02754297 2024-08-21
P-PRRT
CHU de Quebec-Universite Laval
Phase 2 Active not recruiting
NCT06121271 2023-12-07
Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications
University College, London
Phase 2 Not yet recruiting
NCT04385992 2023-06-27
NeoLuPaNET
IRCCS San Raffaele
Phase 2 Completed
NCT05894486 2023-06-08
Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors
Peking University
Phase 2 Not yet recruiting
NCT05513469 2023-04-07
Radio-Marker
Erasmus Medical Center
Phase NA Unknown
NCT01237457 2023-03-20
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Excel Diagnostics and Nuclear Oncology Center
Phase 2 Completed
NCT01842165 2022-11-10
LUMEN
Jules Bordet Institute
Phase 3 Completed
NCT03590119 2022-11-08
LUTIA
UMC Utrecht
Phase 2/3 Completed